ALA Diagnostics activity
ALA Diagnostic is a biotechnology start-up that is developing the first Multiple Sclerosis (“MS”) diagnostic kit based on a patented recombinant protein (only clinically validated existing biomarker for MS diagnosis in blood). The test is fast, easy, cheap, non-invasive, suitable for early diagnosis of MS and easy to integrate into daily clinical routine. ALA is also developing a portfolio of complementary products that includes a diagnostic algorithm and a bioinformatics tool.
Capital increase round led by Beable Capital
Strategic rationale for the deal
This capital increase round allows the Company to perform the international clinical trial and regulatory approval (FDA approval and CE marking) and all the activities necessary to commercialise the product.